How Full FDA Approval Could Spur Vaccination August 13, 2021 Perspective In this Axios column, Drew Altman says full FDA approval of COVID-19 vaccines can provide a big boost to vaccination efforts if treated as an opportunity for updated messaging from government officials at all levels and public health experts and new actions from employers.
The Sleeper Health Cost Policy July 22, 2021 Perspective In this Axios column, Drew Altman unpacks President Biden’s recent executive order on promoting competition, exploring its significance for new efforts to control health costs by addressing consolidation in the health care industry.
A Small Group of Patients Account for a Whole Lot of Spending July 29, 2019 Perspective You have heard about the 5% of the population responsible for 50% of spending. Meet the 1.3%–persistent high spenders with very complex medical needs responsible for 20%. Drew Altman discusses this and possible ways to help them, read the Axios column.
Separating Hype from Reality in Health Tech September 10, 2019 Perspective Drew Altman features exclusive polling for this new Axios column showing how far health information technologies are spreading, but still have a long way to go to disrupt the U.S. health care system.
Health Care Costs as Much as a New Car August 23, 2019 Perspective Health care for a family covered by a large employer cost, on average, $22,885 last year. That’s $2,000 more than the sticker price for a brand-new Volkswagen Beetle. Drew Altman discusses why it matters in this Axios column.
The Only Health Care Prices That Matter to Consumers June 25, 2019 Perspective In this column, Drew Altman zeroes in on a key test for when the implementing rules are written for the new executive order on hospital price transparency: consumers will need to know what amount they must pay out of pocket to really help them shop on price.
Why Doctors and Nurses Can Be Vital Vaccine Messengers April 5, 2021 Perspective In this Axios column, Drew Altman examines why doctors and nurses are such critical messengers in the effort to build vaccine confidence.
Where To Start To Build Vaccine Confidence March 22, 2021 Perspective In this Axios column Drew Altman writes about the recent attention to Republican vaccine resisters. “Republicans and rural Americans are among the most resistant vaccine holdouts and some strategies are emerging to reach them.” But “far from all Republicans are resisters” and “the bigger and quicker payoff will come from prioritizing the more moveable group of ‘wait and see’ Americans.”
Vaccine Confidence Isn’t The Main Obstacle To Reaching Herd Immunity March 1, 2021 Perspective In this Axios column, Drew Altman paints a more optimistic picture of the prospects for getting to herd immunity as vaccine confidence grows, but underscores the urgency of building vaccine confidence in Black and Latino communities where barriers to access and good information are obstacles to getting vaccinated.
Seeing Others Vaccinated May Be The Best Cure For Vaccine Hesitancy February 10, 2021 Perspective In his latest Axios column, Drew Altman shows why vaccine hesitancy will naturally decrease as more and more people see their family members and friends vaccinated without adverse consequences. It’s a hopeful sign about vaccine hesitancy, and should help free up resources to focus on the remaining vaccine hesitant.